Press release
Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026
Chemotherapy and/or radiotherapy is used for the treatment of most cancers. However, chemotherapy and radiotherapy have a very common side effect called neutropenia, and pegfilgrastim is required for its treatment. A study conducted on patients who received chemotherapy in 2016-2017 to evaluate the occurrence of chemotherapy-induced febrile neutropenia (CIFN) showed that, out of 200 patients, 9.5% patients developed neutropenia.Click HERE to Get Synopsis of the Report- https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market
Neutropenia patients are highly susceptible to infections, and for this reason, it is a life-threatening disease. Pegfilgrastim is advantageous over filgrastim in relatively decreasing the incidence of febrile neutropenia. In the future, pegfilgrastim biosimilars will provide better access to this treatment.
The pricing of pegfilgrastim biosimilar is around 25% to 30% lower as compared to originator products (i.e. Neulasta by Amgen). Lower prices of pegfilgrastim biosimilars are expected to enhance their adoption for neutropenia treatment in developed as well as developing countries, as multiple regional and global players are seeking to get marketing approval in various countries.
All in all, rising incidence of cancer and increasing use of chemotherapy for treatment will aid the expansion of the pegfilgrastim biosimilar market, which was valued at US$ 944 Mn in 2019, and is expected to exhibit a CAGR of over 10% over the forecast period (2020–2026).
“Increasing demand for cost-effective therapeutics such as biosimilars and patent expiration of blockbuster biologics will provide competitive benefits to market players in terms of new product development,” says a Fact.MR analyst.
For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=1494
Key Segments of Pegfilgrastim Biosimilar Market
Fact.MR’s study on the pegfilgrastim biosimilar market offers information divided into two important segments— distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories, for the better understanding of readers.
Distribution Channel
Region
Hospital Pharmacies
Retail Pharmacies
Mail-Order Pharmacies
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Takeaways from Pegfilgrastim Biosimilar Market Study
The hospital pharmacies segment under the distribution channel category held half of the global pegfilgrastim biosimilar market share in 2019, owing to increasing cancer treatments such as chemotherapy and others. Retail pharmacies followed due to the increasing number of prescriptions.
North America holds almost 3/4 of the global pegfilgrastim biosimilar market, followed by Europe, owing to large number of product launches in these regions.
The East Asia market year-on-year growth is expected to rapidly surge in the near future. This growth is due to increasing pool of patients and advancements in healthcare with government support, which will propel pegfilgrastim biosimilar market growth in Asian countries.
The COVID-19 pandemic that has swept the world is projected to have only a moderate impact on the progress of the pegfilgrastim biosimilar market.
Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=1494
Increasing Consolidation among Key Players and New Product Launches
Increase in value chain partnerships and market consolidation activities such as collaborations, partnerships, and M&A among market players will be a significant tool to increase their capabilities and speed to market for new launches. For instance, Mylan and Biocon collaboratively worked on a partnership to launch Pegfilgrastim biosimilar Fulphila.
Manufacturers are making efforts to develop biosimilars, and, so far, in 2020, there were 4 biosimilar launches in the United States, and many more are anticipated to be launched. It is estimated that, the pipeline from 2021 to 2025 will have at least 5 approved biosimilars.
For in-depth competitive analysis, buy now- https://www.factmr.com/checkout/1494/S
Looking for More Information?
The research study on the pegfilgrastim biosimilar market by Fact.MR incorporates an unbiased assessment of key demand-driving factors and trends, which have shaped the landscape of the pegfilgrastim biosimilar market over 2018–2019, and includes a detailed assessment of key parameters that are expected to exert influence over 2020–2026. Market statistics have been presented based on distribution channel (hospital pharmacies, retail pharmacies, and mail-order pharmacies), across seven major regions.
For More Insights: http://www.prnewswire.com/news-releases/veterinary-ophthalmic-equipment-market-growth-banking-on-cataract--glaucoma-treatment-advances-for-animals-factmr-301244594.html
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email : sales@factmr.com
Website : https://www.factmr.com
Research Insight: https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market
Content Source: https://www.factmr.com/media-release/1690/global-pegfilgrastim-biosimilar-market
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions.
We have offices in US and Dublin, whereas our global headquarter is in Dubai.While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise.
Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.
Reach out to us with your goals, and we’ll be an able research partner.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026 here
News-ID: 2279221 • Views: …
More Releases from Fact.MR
Desiccant Air Breathers Market to Surpass USD 1.4 Billion by 2035, Driven by Ind …
The global desiccant air breathers market is set for robust growth, increasing from USD 795.8 million in 2025 to USD 1,425.2 million by 2035, reflecting a CAGR of 6.0% over the forecast period. This growth is primarily driven by the need for preventive maintenance and operational efficiency across a wide range of industries.
Desiccant air breathers are essential components used to eliminate moisture and particulate contaminants from the air entering fluid…
Concrete Floor Coatings Market to Reach US$ 2.5 Billion by 2033 Driven by Indust …
According to Fact.MR, the global concrete floor coatings market is valued at US$ 1.4 billion in 2023 and is projected to grow at a CAGR of 6.2%, reaching US$ 2.5 billion by the end of 2033. This growth is closely linked to the ongoing expansion of the global construction industry, with a particular focus on industrial and commercial facilities that require durable, easy-to-maintain, and aesthetically appealing floor surfaces.
With the rise…
Wearable Adhesives Market to Hit US$ 900 Million by 2033, Fueled by Remote Healt …
The global wearable adhesives market is on a steep growth trajectory, expanding from a valuation of US$ 370 million in 2023 to US$ 900 million by 2033. This impressive growth is being driven by a CAGR of 9.3%, supported by increasing demand for remote health monitoring, chronic disease management, and digital healthcare transformation.
Wearable adhesives are critical to the performance and comfort of medical wearables such as ECG monitors, glucose sensors,…
Construction Lasers Market to Reach USD 4.95 Billion by 2035, Driven by Smart Te …
The global construction lasers market is projected to grow significantly, rising from USD 3,124.5 million in 2025 to USD 4,945.9 million by 2035. This steady expansion reflects a compound annual growth rate (CAGR) of 4.7%, primarily fueled by the increasing demand for accuracy, automation, and efficiency in construction workflows across commercial, industrial, and infrastructure projects.
Modern construction demands speed, minimal error margins, and seamless integration with digital design tools like Building…
More Releases for Pegfilgrastim
Global Neulasta (Pegfilgrastim) And Biosimilar Market Size by Application, Type, …
USA, New Jersey- According to Market Research Intellect, the global Neulasta (Pegfilgrastim) And Biosimilar market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
The market for pegfilgrastim and biosimilars is expanding significantly, mostly due to the rising use of chemotherapy-based cancer treatments. By promoting the formation…
Global Pegfilgrastim Market Expects 5.8% Growth Rate from 2021-2028 Amid Rising …
According to the latest report published by Dataintelo, the Global Pegfilgrastim Market is projected to expand at a compound annual growth rate (𝐂𝐀𝐆𝐑) of 5.8% during the period between 2021 and 2028. This significant expansion in the market is primarily driven by the escalating number of cancer cases worldwide and an intensified demand for pegfilgrastim biosimilars.
The report highlights that the evolving global scenario of cancer management and treatment is fostering…
Pegfilgrastim Biosimilars Market Insights, Overview, Share And Forecast To 2033
The pegfilgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.75 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical r&d expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs.
The…
Global Pegfilgrastim Market Analysis Report 2019-2024
This report on Global Pegfilgrastim Market details about the market size, market growth rate and global forecast for the next five years i.e. 2024. The report is a complete analysis assessing the pricing trends, market consumption and sales forecasts. This study covers the competitive landscape by profiling the major market players. The vital information of the market is collected through authentic sources and reviewed by industry experts.
Pegfilgrastim is a PEGylated…
Pegfilgrastim Biosimilar Market: Industry Trends and Developments 2018-2028
Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by…
Pegfilgrastim Industry Business Outlook and Procurement Survey To 2017
Market Reports Center has released its latest research-based report entitled ‘Pegfilgrastim market.' This comprehensive report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Pegfilgrastim market worldwide along with the key trends and latest technologies, playing a prominent role in the Pegfilgrastim market growth over the predicted period. It also takes into account the market trends, aspects like…
